Anthony P Kent1, Martina Brueckmann2, Mandy Fraessdorf3, Stuart J Connolly4, Salim Yusuf4, John W Eikelboom4, Jonas Oldgren5, Paul A Reilly6, Lars Wallentin5, Michael D Ezekowitz7. 1. Department of Internal Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, Connecticut. 2. Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany; University of Heidelberg, Mannheim, Germany. 3. Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany. 4. McMaster University and Hamilton Health Sciences, Population Health Research Institute, Hamilton, Ontario, Canada. 5. Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 6. Clinical Development, Cardiology, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut. 7. Sidney Kimmel Medical College at Thomas Jefferson University and Lankenau and Bryn Mawr Hospitals, Philadelphia, Pennsylvania. Electronic address: michael.ezekowitz@comcast.net.
Abstract
BACKGROUND:Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used medications that can potentially increase the risk of bleeding and thrombosis. OBJECTIVES: This study quantified the effect of NSAIDs in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial. METHODS: This was a post hoc analysis of NSAIDs in the RE-LY study, which compared dabigatran etexilate (DE) 150 and 110 mg twice daily (b.i.d.) with warfarin in patients with atrial fibrillation. Treatment-independent, multivariate-adjusted Cox regression analysis assessed clinical outcomes by comparing NSAID use with no NSAID use. Interaction analysis was obtained from treatment-dependent Cox regression modeling. Time-varying covariate analysis for NSAID use was applied to the Cox model. RESULTS: Among 18,113 patients in the RE-LY study, 2,279 patients used NSAIDs at least once during the trial. Major bleeding was significantly elevated with NSAID use (hazard ratio [HR]: 1.68; 95% confidence interval [CI]: 1.40 to 2.02; p < 0.0001). NSAID use did not significantly alter the risk of major bleeding for DE 150 or 110 mg b.i.d. relative to warfarin (pinteraction = 0.63 and 0.93, respectively). Gastrointestinal major bleeding was significantly elevated with NSAID use (HR: 1.81; 95% CI: 1.35 to 2.43; p < 0.0001). The rate of stroke or systemic embolism (stroke/SE) with NSAID use was significantly elevated (HR: 1.50; 95% CI: 1.12 to 2.01; p = 0.007). The use of NSAIDs did not significantly alter the relative efficacy on stroke/SE for DE 150 or 110 mg b.i.d. relative to warfarin (pinteraction = 0.59 and 0.54, respectively). Myocardial infarction rates were similar with NSAID use compared with no NSAID use (HR: 1.22; 95% CI: 0.77 to 1.93; p = 0.40). Patients were more frequently hospitalized if they used an NSAID (HR: 1.64; 95% CI: 1.51 to 1.77; p < 0.0001). CONCLUSIONS: The use of NSAIDs was associated with increased risk of major bleeding, stroke/SE, and hospitalization. The safety and efficacy of DE 150 and 110 mg b.i.d. relative to warfarin were not altered. (Randomized Evaluation of Long Term Anticoagulant Therapy [RE-LY]; NCT00262600).
RCT Entities:
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used medications that can potentially increase the risk of bleeding and thrombosis. OBJECTIVES: This study quantified the effect of NSAIDs in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial. METHODS: This was a post hoc analysis of NSAIDs in the RE-LY study, which compared dabigatran etexilate (DE) 150 and 110 mg twice daily (b.i.d.) with warfarin in patients with atrial fibrillation. Treatment-independent, multivariate-adjusted Cox regression analysis assessed clinical outcomes by comparing NSAID use with no NSAID use. Interaction analysis was obtained from treatment-dependent Cox regression modeling. Time-varying covariate analysis for NSAID use was applied to the Cox model. RESULTS: Among 18,113 patients in the RE-LY study, 2,279 patients used NSAIDs at least once during the trial. Major bleeding was significantly elevated with NSAID use (hazard ratio [HR]: 1.68; 95% confidence interval [CI]: 1.40 to 2.02; p < 0.0001). NSAID use did not significantly alter the risk of major bleeding for DE 150 or 110 mg b.i.d. relative to warfarin (pinteraction = 0.63 and 0.93, respectively). Gastrointestinal major bleeding was significantly elevated with NSAID use (HR: 1.81; 95% CI: 1.35 to 2.43; p < 0.0001). The rate of stroke or systemic embolism (stroke/SE) with NSAID use was significantly elevated (HR: 1.50; 95% CI: 1.12 to 2.01; p = 0.007). The use of NSAIDs did not significantly alter the relative efficacy on stroke/SE for DE 150 or 110 mg b.i.d. relative to warfarin (pinteraction = 0.59 and 0.54, respectively). Myocardial infarction rates were similar with NSAID use compared with no NSAID use (HR: 1.22; 95% CI: 0.77 to 1.93; p = 0.40). Patients were more frequently hospitalized if they used an NSAID (HR: 1.64; 95% CI: 1.51 to 1.77; p < 0.0001). CONCLUSIONS: The use of NSAIDs was associated with increased risk of major bleeding, stroke/SE, and hospitalization. The safety and efficacy of DE 150 and 110 mg b.i.d. relative to warfarin were not altered. (Randomized Evaluation of Long Term Anticoagulant Therapy [RE-LY]; NCT00262600).
Authors: Meijia Zhou; Charles E Leonard; Colleen M Brensinger; Warren B Bilker; Stephen E Kimmel; Todd E H Hecht; Sean Hennessy Journal: Clin Pharmacol Ther Date: 2020-05-16 Impact factor: 6.875
Authors: Lorenzo Villa Zapata; Philip D Hansten; Jennifer Panic; John R Horn; Richard D Boyce; Sheila Gephart; Vignesh Subbian; Andrew Romero; Daniel C Malone Journal: Thromb Haemost Date: 2020-05-26 Impact factor: 5.249
Authors: Celine Gallagher; Karin Nyfort-Hansen; Debra Rowett; Christopher X Wong; Melissa E Middeldorp; Rajiv Mahajan; Dennis H Lau; Prashanthan Sanders; Jeroen M Hendriks Journal: Open Heart Date: 2020-04-06
Authors: Woldesellassie M Bezabhe; Luke R Bereznicki; Jan Radford; Barbara C Wimmer; Mohammed S Salahudeen; Ivan Bindoff; Edward Garrahy; Gregory M Peterson Journal: J Clin Med Date: 2020-11-05 Impact factor: 4.241
Authors: Alberto Magni; Piergiuseppe Agostoni; Cesare Bonezzi; Giuseppe Massazza; Paolo Menè; Vincenzo Savarino; Diego Fornasari Journal: Pain Ther Date: 2021-04-19
Authors: Hawa O Abu; Jane S Saczynski; John Ware; Jordy Mehawej; Tenes Paul; Hamza Awad; Benita A Bamgbade; Isabelle C Pierre-Louis; Mayra Tisminetzky; Catarina I Kiefe; Robert J Goldberg; David D McManus Journal: Qual Life Res Date: 2020-07-11 Impact factor: 3.440